logo-loader
viewGoldilocks Therapeutics

Goldilocks Therapeutics' nanoparticles delivered to the kidney are 'not too big, not too small'

Goldilocks Therapeutics Inc CEO Arthur Klausner sat down with Proactive's Christine Corrado at BIO CEO in New York.

The New York-based early-stage bio-pharmaceutical company's kidney-targeting "mesoscale nanoparticle" technology was developed at Memorial Sloan Kettering Cancer Center for the prevention and treatment of acute kidney injury and polycystic kidney disease.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Emmerson 'bolster cash position to help with ongoing negotiations with...

Emmerson PLC's (LON:EML) Graham Clarke talks to proactive London about raising £5.5mln in a placing of shares at an issue price of 5.75p. Clarke explains, this helps to 'bolster our cash position to help with ongoing negotiations with potential strategic partners'. The money raised will be...

2 hours, 9 minutes ago

2 min read